Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.10 – $1.17
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.9M | $11.6M | $7.5M | $9.9M | $15.5M | $9.4M | $0 | $0 |
| Cost of revenue | $6.8M | $6.3M | $9.8M | $19.2M | $17.1M | $12.0M | $0 | $0 |
| Gross profit | $2.1M | $5.3M | −$2.2M | −$9.3M | −$1.5M | −$2.6M | $0 | $0 |
| Gross margin | 23.7% | 45.6% | -29.7% | -94.2% | -10.0% | -27.4% | — | — |
| R&D | $18.6M | $6.1M | $13.6M | $22.4M | $23.6M | $32.1M | $0 | $0 |
| Operating income | −$30.7M | −$20.1M | −$24.9M | −$42.0M | −$40.4M | −$92.2M | $788.7K | −$678.7K |
| EBITDA | −$25.8M | −$13.2M | −$20.6M | −$31.8M | −$34.5M | −$98.4M | $3.7M | −$678.7K |
| Net income | −$29.2M | −$21.6M | −$29.9M | −$41.3M | −$43.4M | −$105.2M | $1.0M | −$653.0K |
| Net margin | -327.0% | -186.6% | -396.1% | -417.8% | -279.1% | -1115.0% | — | — |
| EPS (diluted) | -9.48 | -7.50 | -9.49 | -11.72 | -10.13 | -19.50 | 0.14 | -0.09 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $60M | $2.45 | $2.45–$2.45 | 1 |
| 2027 | $77M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
EVONEXT HLDGS SA
No one on the platform currently holds ELVAF.
No tracked institution reports a position in ELVAF as of their last filing.
No one on the platform has traded ELVAF yet.
| $14M |
| — |
| HSITFHadasit Bio-Holdings Ltd | $0.12 | +0.00% | $1M | — |
| MRESInstitute of Biomedical Research Corp. | $0.00 | -14.62% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.2× sales vs its 0.0× historical median P/S.
Fair value ≈ $0.28 · price $1.10 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ELVAF I got my eyes on this company. More closely "Nootka Shield"
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.